Results 131 to 140 of about 6,506,258 (188)
ABSTRACT Standardized uptake value maximum (SUVmax), metabolic tumor volumes (MTV), and total lesion glycolysis (TLG) are metabolic parameters used to quantify tumors detected on fluorine‐18 fluorodeoxyglucose positron emission tomography/computed tomography (18F‐FDG PET/CT).
Jesse Johnson +3 more
wiley +1 more source
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma; the complete response rate for standard therapies in use today is 85 - 90%. NVP-BEZ235 inhibits the PI3K/Akt/mTOR signaling axis at the level of both PI3K and mTOR.
COSENZA, Maria +4 more
core +1 more source
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs +15 more
wiley +1 more source
Mantle cell lymphoma presenting as solitary polypoid colonic lesions
Mantle cell lymphoma of the intestine is rare, usually presenting as multiple small polyps. We report three men with colonic mantle cell lymphoma in the form of single large polypoid mass.
Hussainy, A S +3 more
core
Beneath the Mantle of Mantle Cell Lymphoma
openaire +2 more sources
Central nervous system (CNS) involvement in mantle cell lymphoma (MCL) is uncommon, and the manifestations and natural history are not well described.We present the data on 57 patients with MCL who developed CNS involvement, from a database of 1396 ...
Pavel Klener +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Best Practice & Research Clinical Haematology, 2012
MCL is a well-characterized clinically aggressive lymphoma with a poor prognosis. Recent research findings have slightly improved the outcome of this neoplasm. The addition of rituximab to conventional chemotherapy has increased overall response rates, but it does not improve overall survival with respect to chemotherapy alone.
Cortelazzo S +3 more
openaire +5 more sources
MCL is a well-characterized clinically aggressive lymphoma with a poor prognosis. Recent research findings have slightly improved the outcome of this neoplasm. The addition of rituximab to conventional chemotherapy has increased overall response rates, but it does not improve overall survival with respect to chemotherapy alone.
Cortelazzo S +3 more
openaire +5 more sources

